Clinical Trials in Connecticut, 2026, page 2 of 3

Trials with a site in Connecticut

Status

Study

Lead sponsor

Phase

Enrol

US states

Start

Active, closed

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

NCT06625060Episodic Migraine, Chronic Migraine

DrugCorabotase

Ipsen

Phase 2

670

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Louisiana

2024-10-10

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

NCT06630286HIV-1-infection

DrugsISL/LEN·B/F/TAF

Gilead Sciences

Phase 3

609

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2024-10-09

Recruiting

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

NCT06525636X-linked Hypophosphatemia

Kyowa Kirin Co., Ltd.

Phase 1/2

California, Connecticut, Indiana, Minnesota, Tennessee

2024-10-09

Active, closed

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

NCT06672055SARS-CoV2, COVID-19

DrugComirnaty

Vaxart

Phase 2

5,485

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2024-10-08

Active, closed

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299HIV-1-Infection

DrugsAntiretroviral Combinations·ISL/LEN

Gilead Sciences

Phase 3

600

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2024-10-08

Recruiting

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

NCT06559891Hypertension

SoniVie Inc.

Not applicable

261

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Illinois, Louisiana

2024-10-03

Recruiting

A Study of BG-C477 in Participants With Advanced Solid Tumors

NCT06596473Advanced Solid Tumors

DrugTislelizumab

BeOne Medicines

Phase 1

310

Arizona, California, Colorado, Connecticut, Illinois, Kansas, Mississippi, New Jersey

2024-10-03

Recruiting

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype

DrugsBelinostat·Pralatrexate·Soquelitinib

Corvus Pharmaceuticals, Inc.

Phase 3

150

California, Connecticut, Florida, Georgia, Illinois, Iowa, Maryland, Massachusetts

2024-10-02

Recruiting

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

DrugsNadofaragene Firadenovec·Docetaxel·Gemcitabine·Pembrolizumab

Ferring Pharmaceuticals

Phase 3

250

Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2024-10-01

Active, closed

SIMPLAAFY Clinical Trial

NCT06521463Atrial Fibrillation, Stroke, Bleeding

Boston Scientific Corporation

Not applicable

1,857

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2024-10-01

Active, closed

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

NCT06602258Alzheimer's Disease

DrugsE2814·Lecanemab

Eisai Inc.

Phase 2

105

Arizona, Connecticut, Florida, Georgia, Mississippi, Missouri, Pennsylvania, Tennessee

2024-09-30

Recruiting

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

NCT06551142Neoplasms

DrugsRis-Rez·Tarlatamab·Dostarlimab·Cetuximab

GlaxoSmithKline

Phase 1

845

California, Colorado, Connecticut, Indiana, Massachusetts, Michigan, New Jersey, South Carolina

2024-09-30

Recruiting

Registry for Stage 2 Type 1 Diabetes

NCT06481904Type 1 Diabetes

DrugTzield

Sanofi

Observational

200

California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky

2024-09-27

Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

Stemline Therapeutics, Inc.

Phase 3

4,220

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2024-09-27

Recruiting

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507Netherton Syndrome

BioCryst Pharmaceuticals

Phase 1

California, Connecticut, Illinois, Indiana

2024-09-26

Active, closed

A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System

NCT06564636Total Hip Arthroplasty (THA), Osteoarthritis, Degenerative Joint Disease, Inflammatory Arthritis

Smith & Nephew, Inc.

Observational

119

California, Connecticut, Florida, Illinois, New York, North Carolina

2024-09-26

Recruiting

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787Alzheimer Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

406

Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Mississippi

2024-09-26

Active, closed

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer

DrugsDivarasib·Adagrasib·Sotorasib

Hoffmann-La Roche

Phase 3

338

Arizona, California, Connecticut, Florida, Illinois, Maine, Massachusetts, Michigan

2024-09-23

Recruiting

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

NCT06413680Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors

DrugsREGN10597·Cemiplimab

Regeneron Pharmaceuticals

Phase 1/2

240

California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas

2024-09-23

Recruiting

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

NCT06633016Major Depressive Disorder

DrugABX-002

Autobahn Therapeutics, Inc.

Phase 2

230

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts

2024-09-20

Active, closed

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027Parkinson Disease

Cerevance

Phase 3

330

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas

2024-09-20

Active, closed

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951Melanoma

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

151

California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey

2024-09-18

Active, closed

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

NCT06559163Systemic Lupus Erythematosus

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

190

Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland

2024-09-17

Active, closed

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer

DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel

Amgen

Phase 1

California, Colorado, Connecticut, Minnesota, Missouri, Nevada, New York, Oklahoma

2024-09-17

Active, closed

Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery

NCT06642051Chronic Venous Insufficiency, CVI, Venous Malformations, Venous Leg Ulcers, Klippel-Trenaunay Syndrome

Sonablate

Not applicable

Connecticut

2024-09-11

Recruiting

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789Hemophilia B

Regeneron Pharmaceuticals

Phase 1/2

130

California, Colorado, Connecticut, Florida, Indiana, Louisiana, Michigan, Ohio

2024-09-11

Active, closed

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06417775Migraine

DrugUbrogepant

AbbVie

Phase 3

496

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii

2024-09-10

Recruiting

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

NCT06246916Melanoma

DrugsFianlimab·Relatlimab·Cemiplimab·Nivolumab

Regeneron Pharmaceuticals

Phase 3

560

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho

2024-09-09

Recruiting

RevCore for In Stent Thrombosis

NCT06394739In-stent Thrombosis

Inari Medical

Observational

100

Connecticut, District of Columbia, Idaho, Maryland, New York, North Carolina, Ohio, Pennsylvania

2024-09-09

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

DrugGlofitamab

Arvinas Inc.

Phase 1

329

Connecticut, Florida, Michigan, New Jersey, New York, Ohio, Tennessee, Texas

2024-09-05

Recruiting

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

2,150

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2024-09-04

Recruiting

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542Crohn's Disease

DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab

AbbVie

Phase 2

590

Alabama, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois

2024-09-04

Recruiting

PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm

NCT06445608Coronary Artery Disease

Kardion Inc

Not applicable

310

Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Indiana, Massachusetts

2024-09-03

Not yet open

Preterm Infants Fed a Human Milk Fortifier

NCT05551975Growth

Abbott Nutrition

Not applicable

321

Arizona, Arkansas, Connecticut, Florida, Massachusetts, Missouri, New Mexico, New York

2024-09

Active, closed

LMN-201 for Prevention of C. Difficile Infection Recurrence

NCT05330182Clostridioides Difficile Infection

Lumen Bioscience, Inc.

Phase 2/3

375

California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota, New York

2024-08-29

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana

2024-08-28

Recruiting

A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

NCT06565195Parkinson's Disease

Prevail Therapeutics

Phase 1

124

Colorado, Connecticut, Florida, Illinois, Michigan, Pennsylvania, Texas

2024-08-27

Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884Multiple Myeloma

DrugsRamantamig·Talquetamab

Janssen Research & Development, LLC

Phase 2

210

California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington

2024-08-26

Active, closed

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers

DrugsEribulin·Pumitamig·Gemcitabine·Paclitaxel

BioNTech SE

Phase 2

California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, New York, Tennessee

2024-08-26

Active, closed

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

NCT06556368Wet Age-related Macular Degeneration

DrugsTabirafusp tedromer·Eylea·Aflibercept

Kodiak Sciences Inc

Phase 3

675

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana

2024-08-23

Active, closed

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

NCT06577090Obesity

Skye Bioscience, Inc.

Phase 2

136

Alabama, California, Connecticut, Georgia, Kentucky, Nebraska, Nevada, New Hampshire

2024-08-22

Recruiting

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy

DrugsRiliprubart·IVIG

Sanofi

Phase 3

160

Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas

2024-08-21

Recruiting

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)

NCT06315738Necrotizing Enterocolitis

Noveome Biotherapeutics, formerly Stemnion

Phase 1/2

Arkansas, Connecticut, Florida, Illinois, Oklahoma, Pennsylvania

2024-08-19

Recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma

DrugZilovertamab vedotin

Merck Sharp & Dohme LLC

Phase 1/2

California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri

2024-08-16

Recruiting

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT06332534Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

110

California, Colorado, Connecticut, Illinois, Indiana, Massachusetts, Minnesota, New York

2024-08-08

Recruiting

A Study to Assess Growth in Children With Idiopathic Short Stature

NCT06309979Idiopathic Short Stature

BioMarin Pharmaceutical

Observational

300

Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Kentucky

2024-08-08

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRestoret·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Iowa

2024-08-07

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida

2024-08-07

Recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019Chronic Lymphocytic Leukemia

DrugsAcalabrutinib·Obinutuzumab·Venetoclax

AbbVie

Phase 3

170

Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa

2024-08-05

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2024-07-30

Recruiting

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306Depressive Disorder, Major

DrugSeltorexant

Janssen Research & Development, LLC

Phase 3

752

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2024-07-25

Active, closed

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

NCT06491914Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema

DrugAflibercept

Regeneron Pharmaceuticals

Phase 3

1,126

California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland

2024-07-24

Active, closed

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616Alzheimer Disease

Janssen Pharmaceutica N.V., Belgium

Phase 2

Arizona, California, Connecticut, Florida, Illinois, Michigan, Mississippi, New Jersey

2024-07-22

Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752Relapsing Multiple Sclerosis, Multiple Sclerosis

TG Therapeutics, Inc.

Observational

2,000

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2024-07-22

Active, closed

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

NCT06384261Leukemia, Myeloid, Acute

DrugsCusatuzumab·Azacitidine·Venetoclax

OncoVerity, Inc.

Phase 2

140

Arizona, California, Colorado, Connecticut, Florida, Iowa, Kentucky, New Jersey

2024-07-22

Recruiting

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

NCT06481306Anemia, Sickle Cell, Healthy Volunteers

DrugsFamotidine·Pantoprazole

Bristol-Myers Squibb

Phase 1/2

224

Alabama, California, Connecticut, Georgia, Illinois, Kansas, Maryland, Massachusetts

2024-07-17

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsLumakras·Sotorasib·Bevacizumab-awwb·Panitumumab

Amgen

Phase 3

450

Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Michigan

2024-07-17

Active, closed

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

NCT06427395Primary Biliary Cholangitis

DrugSaroglitazar Magnesium

Zydus Therapeutics Inc.

Phase 3

102

California, Colorado, Connecticut, Florida, Georgia, Indiana, New York, North Carolina

2024-07-16

Recruiting

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT05952024Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Rituximab

AstraZeneca

Phase 2

California, Connecticut, Florida, Iowa, Kentucky, Maryland, Michigan, South Dakota

2024-07-16

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Arizona, California, Colorado, Connecticut, Indiana, Michigan, Nevada, North Carolina

2024-07-16

Active, closed

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

NCT06096779Hepatocellular Carcinoma

DrugsTecentriq·Avastin·Atezolizumab·Bevacizumab

Genentech, Inc.

Phase 2

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kentucky

2024-07-15

Recruiting

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients

NCT06284590Melanoma Stage III, Melanoma Stage IV

DrugsDaromun·L19IL2·Onfekafusp alfa·Keytruda

Philogen S.p.A.

Phase 2

162

Connecticut, New York

2024-07-12

Active, closed

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic

DrugRiliprubart

Sanofi

Phase 3

109

Alabama, California, Colorado, Connecticut, Florida, Illinois, Kansas, Louisiana

2024-07-12

Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

DrugIvosidenib

Servier Bio-Innovation LLC

Phase 3

136

California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa, Maryland

2024-07-09

Recruiting

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

NCT06328777Systemic Sclerosis, Scleroderma, Interstitial Lung Diseases

DrugRese-cel

Cabaletta Bio

Phase 2/3

Connecticut, Florida, Illinois, Kansas, Michigan, Minnesota, New York, North Carolina

2024-07-02

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana

2024-06-29

Recruiting

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

NCT06263231Sarcoma,Soft Tissue

DrugsINT230-6·Trabectedin·Pazopanib·Eribulin

Intensity Therapeutics, Inc.

Phase 3

333

California, Connecticut, Michigan, Nebraska, North Carolina, Ohio, Pennsylvania

2024-06-28

Active, closed

A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

NCT06455098Atrial Fibrillation

Biosense Webster, Inc.

Not applicable

354

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland

2024-06-28

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Ado-trastuzumab emtansine·Trastuzumab emtansine

Boehringer Ingelheim

Phase 1/2

768

California, Connecticut, Florida, Illinois, Indiana, Iowa, Massachusetts, Michigan

2024-06-28

Recruiting

Global Paradise System US Post Approval Study

NCT06297291Hypertension, Cardiovascular Diseases, Vascular Diseases

ReCor Medical, Inc.

Observational

1,000

California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas, Louisiana

2024-06-28

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho

2024-06-27

Recruiting

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

NCT06207032Cancer

Tempus AI

Observational

500

Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky

2024-06-26

Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR

AstraZeneca

Observational

1,850

California, Connecticut, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Minnesota

2024-06-25

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia

2024-06-25

Recruiting

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587Generalized Myasthenia Gravis

DrugCladribine

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3

264

Arizona, Colorado, Connecticut, District of Columbia, Florida, Kansas, North Carolina, Ohio

2024-06-25

Recruiting

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374Triple-Negative Breast Cancer

DrugsXeloda·Sacituzumab tirumotecan·Keytruda·Capecitabine

Merck Sharp & Dohme LLC

Phase 3

1,530

Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia

2024-06-24

Recruiting

Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding

NCT06188585Acute Gastrointestinal Bleeding

Medtronic - MITG

Not applicable

278

Connecticut, Illinois, Massachusetts, New Jersey, New York

2024-06-21

Active, closed

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

NCT05897424Alpha 1-Antitrypsin Deficiency, Emphysema

Sanofi

Phase 2

185

Alabama, Arizona, California, Colorado, Connecticut, Florida, Indiana, Massachusetts

2024-06-20

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois

2024-06-20

Recruiting

Study of SGR-3515 In Participants With Advanced Solid Tumors.

NCT06463340Advanced Solid Tumor

Schrödinger, Inc.

Phase 1

Connecticut, Illinois, Michigan, New York, North Carolina, Ohio, Oklahoma, Tennessee

2024-06-18

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Alabama, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana

2024-06-17

By invitation

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

NCT06363760Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies

Editas Medicine, Inc.

Observational

California, Colorado, Connecticut, Florida, Georgia, Minnesota, New York, North Carolina

2024-06-17

Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

NCT06389136Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

200

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho

2024-06-14

Recruiting

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer

DrugTUB-040

Gilead Sciences

Phase 1/2

250

Alabama, Connecticut, Georgia, Kentucky, Massachusetts, New Jersey, New York, Ohio

2024-06-12

Recruiting

MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion

NCT05037968Degenerative Disc Disease, Spine Fusion, Leg Pain and/or Back Pain

Kuros Biosurgery AG

Not applicable

100

Connecticut, Illinois, Maryland, Michigan, North Carolina, Ohio, Utah, Virginia

2024-06-10

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas

2024-06-05

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Massachusetts

2024-06-05

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2024-06-05

Recruiting

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

NCT06459973Advanced Solid Tumors

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

252

Colorado, Connecticut, Florida, Kentucky, Missouri, Nevada, New Mexico, Oklahoma

2024-06-04

Active, closed

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

NCT06106672Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG

COUR Pharmaceutical Development Company, Inc.

Phase 1/2

Arizona, California, Connecticut, Florida, Illinois, Kansas, Michigan, Missouri

2024-05-30

Active, closed

ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)

NCT06373731Age Related Macular Degeneration (ARMD)

DrugElamipretide

Stealth BioTherapeutics Inc.

Phase 3

313

Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland

2024-05-30

Active, closed

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel

Amgen

Phase 1

120

California, Colorado, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Missouri

2024-05-29

Active, closed

A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM

NCT06167655Headache Migraine Chronic

ShiraTronics

Not applicable

250

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois

2024-05-29

Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729Non-small Cell Lung Cancer

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

348

California, Connecticut, Florida, Illinois, Missouri, Montana, New Jersey, New York

2024-05-24

Recruiting

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC

DrugsRMC-9805·MFOLFIRINOX·MFOLFOX6·Folfiri

Revolution Medicines, Inc.

Phase 1/2

1,130

Arizona, California, Colorado, Connecticut, Florida, Kansas, Maryland, Massachusetts

2024-05-24

Recruiting

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C

DrugsBBO-10203·Pembrolizumab

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Phase 1

350

Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan

2024-05-22

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois

2024-05-20

Active, closed

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

NCT06393712Cerebral Amyloid Angiopathy

DrugsAln-App·Mivelsiran

Alnylam Pharmaceuticals

Phase 2

210

California, Colorado, Connecticut, Florida, Illinois, Kentucky, Louisiana, Massachusetts

2024-05-17

Recruiting

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

NCT06116110Non Hodgkin Lymphoma, Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma

Miltenyi Biomedicine GmbH

Observational

150

Arizona, California, Connecticut, Illinois, Kansas, Maryland, Massachusetts, North Carolina

2024-05-15

Active, closed

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

NCT06321302Diabetic Retinopathy

Boehringer Ingelheim

Phase 2

190

Arizona, California, Colorado, Connecticut, Florida, Hawaii, Maine, Maryland

2024-05-15

Active, closed

Clinical Study of External Electrical Stimulation for Male Incontinence

NCT06620419Urinary Incontinence

Elidah, Inc.

Not applicable

Connecticut

2024-05-15

Recruiting

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

NCT06635954Cancer, Immunotherapy, PD-1, PD-L1

Oxford Biodynamics Inc.

Observational

2,000

Connecticut, Georgia, South Carolina

2024-05-14

Active, closed

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Arizona, Arkansas, California, Connecticut, Florida, Georgia, Kentucky, Louisiana

2024-05-13

Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

NCT06395519Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer

858 Therapeutics, Inc.

Phase 1/2

120

Arizona, Connecticut, Florida, Illinois, Massachusetts, Minnesota, New York, Ohio

2024-05-13

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois

2024-05-08

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida

2024-05-06

Active, closed

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT05973487Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma

TScan Therapeutics, Inc.

Phase 1

840

Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota

2024-05-06

Recruiting

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

NCT06384352Advanced Solid Tumors

DrugsPemetrexed·Cisplatin·Carboplatin·Pembrolizumab

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1

500

Colorado, Connecticut, Florida, Nevada, Ohio, Texas

2024-05-01

By invitation

A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

NCT06431893Homocystinuria

DrugPegtibatinase

Travere Therapeutics, Inc.

Phase 3

100

Arizona, Connecticut, Georgia, Illinois, Maine, Maryland, New York, North Carolina

2024-04-30

Active, closed

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

DrugRetatrutide

Eli Lilly and Company

Phase 3

10,000

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2024-04-30

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maryland

2024-04-29

Recruiting

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

NCT06234605Renal Cell Carcinoma

DrugBelzutifan

HiberCell, Inc.

Phase 1

Arizona, California, Colorado, Connecticut, Michigan, Minnesota, Missouri, New York

2024-04-29

Active, closed

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

470

California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Maryland

2024-04-29

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia

2024-04-27

Recruiting

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

NCT06345339Hypothyroidism

DrugLevothyroxine

AbbVie

Phase 2/3

2,800

Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois

2024-04-26

Recruiting

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

NCT06413433Binge-Eating Disorder

DrugSolriamfetol

Axsome Therapeutics, Inc.

Phase 3

450

California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri

2024-04-26

Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080Squamous Cell Carcinoma of Head and Neck

DrugsAmivantamab·Paraplatin·Taxol·Keytruda

Janssen Research & Development, LLC

Phase 1/2

287

California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Missouri

2024-04-22

Recruiting

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

NCT06045754Crohn's Disease

DrugsHumira·Ustekinumab·Vedolizumab·Adalimumab

Takeda

Phase 4

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas

2024-04-18

Recruiting

The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).

NCT02998229Intracranial Aneurysm

Medtronic Neurovascular Clinical Affairs

Not applicable

300

California, Colorado, Connecticut, Florida, Illinois, Indiana, Iowa, Massachusetts

2024-04-16

Recruiting

MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

NCT05908331In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease

Concept Medical Inc.

Not applicable

492

Alabama, Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Minnesota

2024-04-16

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

NCT06312176Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

1,200

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky

2024-04-14

Active, closed

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

NCT06307431Renal Cell Carcinoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

272

California, Connecticut, Massachusetts, New York, North Carolina, Pennsylvania, Texas

2024-04-10

Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

NCT06326411Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation

Nested Therapeutics, Inc

Phase 1

230

California, Colorado, Connecticut, Florida, New York, Pennsylvania, Tennessee, Texas

2024-04-09

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

375

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2024-04-03

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky

2024-04-03

Active, closed

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer

Ipsen

Phase 1/2

California, Connecticut, Tennessee, Virginia

2024-04-03

Active, closed

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

NCT06079372Hypophosphatasia

DrugsAsfotase alfa·ALXN1850

Alexion Pharmaceuticals, Inc.

Phase 3

Connecticut, Maryland, Minnesota, Missouri, North Carolina, Tennessee

2024-04-02

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727Solid Tumor, Adult

DrugsCRB-701·Anti-PD-1

Corbus Pharmaceuticals Inc.

Phase 1/2

348

Alabama, California, Colorado, Connecticut, Florida, Illinois, Massachusetts, Nebraska

2024-04-01

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2024-03-29

Active, closed

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201Multiple Sclerosis, Myasthenia Gravis

DrugsZola-cel·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

120

Alabama, California, Colorado, Connecticut, Kansas, Massachusetts, Missouri, New Jersey

2024-03-28

Active, closed

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)

NCT06358651Social Anxiety Disorder

DrugFasedienol

VistaGen Therapeutics, Inc.

Phase 3

238

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Kansas

2024-03-28

Active, closed

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808HIV-1-infection

DrugsBictegravir·B/F/TAF·Lenacapavir

Gilead Sciences

Phase 3

577

Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan

2024-03-25

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

NCT06256588Neoplasms, Head and Neck

DrugDostarlimab

GlaxoSmithKline

Phase 3

864

Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Iowa

2024-03-21

Active, closed

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

NCT06041386Asthma

DrugMepolizumab

GlaxoSmithKline

Phase 4

336

California, Colorado, Connecticut, Florida, Georgia, Kentucky, Louisiana, Maryland

2024-03-20

Active, closed

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

NCT06268886Alzheimer Disease, Early Onset

DrugMoponetug

Bristol-Myers Squibb

Phase 2

310

Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, New Hampshire

2024-03-20

Recruiting

Strategy for Improving Stroke Treatment Response

NCT05948566Ischemic Stroke

DrugTS23

Translational Sciences, Inc.

Phase 2

300

Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois

2024-03-18

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana

2024-03-18

Active, closed

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06132893Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii

2024-03-14

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT05923073Crohn's Disease

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 3

120

California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio

2024-03-13

Recruiting

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT05509777Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

California, Connecticut, Georgia, Indiana, Massachusetts, New Jersey, New York, Ohio

2024-03-13

Active, closed

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06318273Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1

152

California, Connecticut, Florida, Illinois, Michigan, North Carolina, Rhode Island, Texas

2024-03-08

Active, closed

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor

Affini-T Therapeutics, Inc.

Phase 1/2

100

California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin

2024-03-06

Active, closed

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

17,300

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2024-03-05

Active, closed

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

NCT06335173Alzheimer Disease

Acumen Pharmaceuticals

Phase 2

542

California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Mississippi

2024-02-29

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Alaska, Connecticut, Florida, Indiana, Kentucky, Massachusetts, Missouri, New Jersey

2024-02-27

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

740

California, Connecticut, Florida, Illinois, Maryland, Minnesota, Missouri, New York

2024-02-26

Recruiting

SNV1521 in Participants With Advanced Solid Tumors

NCT06220864Advanced Solid Tumor

DrugsDB-1310·Abiraterone·Darolutamide

Synnovation Therapeutics, Inc.

Phase 1

400

Connecticut, Pennsylvania, Tennessee, Texas, Utah

2024-02-23

Active, closed

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

NCT06282159Myasthenia Gravis, Generalized

DrugClaseprubart

Dianthus Therapeutics

Phase 2

Arizona, California, Connecticut, Florida, Illinois, Kansas, Kentucky, Massachusetts

2024-02-23

Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06001788AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar

DrugsXospata·Granulocyte Colony-Stimulating Factor·Ziftomenib·Idarubicin

Kura Oncology, Inc.

Phase 1

171

Arizona, California, Colorado, Connecticut, Georgia, Illinois, Iowa, Kansas

2024-02-22

Recruiting

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

NCT06035120Emphysema, Pulmonary, Emphysema or COPD

Pulmonx Corporation

Not applicable

200

Arizona, Colorado, Connecticut, Florida, Illinois, Kentucky, Massachusetts, Michigan

2024-02-22

Active, closed

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 3

404

California, Connecticut, Florida, Kentucky, Louisiana, New Jersey, New York, North Carolina

2024-02-20

Active, closed

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

NCT06206837Breast Cancer

DrugsVepdegestrant·Atirmociclib

Pfizer

Phase 1/2

Arkansas, California, Colorado, Connecticut, Michigan, New Jersey, New York, Texas

2024-02-19

Recruiting

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

NCT06121297Systemic Lupus Erythematosus, Lupus Nephritis

DrugRese-cel

Cabaletta Bio

Phase 1/2

California, Connecticut, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota

2024-02-16

Recruiting

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

NCT06234423Ovarian Cancer, Solid Tumor

OnCusp Therapeutics, Inc.

Phase 1

263

Colorado, Connecticut, Florida, Massachusetts, Michigan, New York, Oklahoma, Tennessee

2024-02-09

Recruiting

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

NCT06196203Higher-risk Myelodysplastic Syndromes

DrugsLigufalimab·Azacitidine

Akeso

Phase 2

California, Colorado, Connecticut, Florida, Maryland, Missouri, New York, North Carolina

2024-02-07

By invitation

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

NCT06270719Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc.

Observational

500

Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana

2024-02-07

Recruiting

QTX3034 in Patients With KRAS G12D Mutation

NCT06227377Solid Tumors

Quanta Therapeutics

Phase 1

250

California, Colorado, Connecticut, Florida, New York, North Carolina, Oklahoma, Tennessee

2024-02-05

Recruiting

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT05571059Idiopathic Pulmonary Fibrosis

DrugIfetroban

Cumberland Pharmaceuticals

Phase 2

128

California, Connecticut, Florida, Illinois, Indiana, Kansas, Kentucky, Michigan

2024-01-31

Recruiting

Accuro XV Ultrasound Imaging System for BoneEnhance and Fracture Detection Algorithms

NCT07853768Fracture Arm, Fracture Leg, Wrist Injury, Ankle Injury

Rivanna Medical, Inc.

Not applicable

25,000

California, Colorado, Connecticut, Texas, Utah, Virginia

2024-01-29

Active, closed

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

NCT06223958Neovascular Age-Related Macular Degeneration

DrugsOtx-Tki·Aflibercept

Ocular Therapeutix, Inc.

Phase 3

344

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana

2024-01-29

Active, closed

Registry of the Patient Experience for Carpal Tunnel Release

NCT06071468Carpal Tunnel Syndrome, CTS

Sonex Health, Inc.

Observational

1,424

Alabama, Arizona, Connecticut, Florida, Indiana, Massachusetts, Michigan, Minnesota

2024-01-26

Recruiting

STIMIT Activator 1 IDE Study

NCT05883163Diaphragm Issues

Stimit AG

Not applicable

Connecticut, Massachusetts, Virginia

2024-01-24

Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06153251Relapsed and/or Refractory Multiple Myeloma

DrugsFludara·Cytoxan·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

187

Alabama, California, Colorado, Connecticut, Florida, Massachusetts, New York, Tennessee

2024-01-23

Recruiting

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

NCT06179069SCLC

DrugsZL-1310·Atezolizumab·Carboplatin

Zai Lab (Shanghai) Co., Ltd.

Phase 1

339

California, Connecticut, Florida, Michigan, New Jersey, New York, North Carolina, Ohio

2024-01-23

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

California, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Iowa

2024-01-22

Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

NCT06130553Advanced Solid Tumors That Are MTAP Deficient

DrugsAZD3470·Dato-DXd

AstraZeneca

Phase 1/2

334

California, Connecticut, Maryland, Oregon, Pennsylvania, Rhode Island, Virginia

2024-01-18

Active, closed

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy

NCT05568459Hemophilia B

Regeneron Pharmaceuticals

Observational

Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana, Michigan, Ohio

2024-01-17

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsErbitux·Cetuximab

AVEO Pharmaceuticals, Inc.

Phase 3

410

Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas

2024-01-11

Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

NCT06241456Advanced Solid Tumor

DrugsFludara·Bendamustine·Cetuximab·Fludarabine

Fate Therapeutics

Phase 1

351

Arizona, California, Connecticut, Illinois, Michigan, Minnesota, Missouri, New York

2024-01-05

Recruiting

BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears

NCT05997381Rotator Cuff Tears

CONMED Corporation

Not applicable

268

Connecticut

2024-01-05

Active, closed

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

NCT05820087Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor

HistoSonics, Inc.

Not applicable

California, Connecticut, Florida, Maryland, Massachusetts, New York, Ohio, Texas

2024-01-04

By invitation

RNA Assays for Endometriosis Detection and Diagnosis

NCT06907303Endometriosis

Wren Laboratories LLC

Observational

400

Connecticut

2024-01-01

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624Prostate Cancer Metastatic

DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone

Merck Sharp & Dohme LLC

Phase 3

1,310

California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Louisiana

2023-12-31

Recruiting

Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment

NCT06247085Homocystinuria

DrugPegtibatinase

Travere Therapeutics, Inc.

Phase 3

Arizona, Connecticut, Georgia, Illinois, Maine, Maryland, New York, North Carolina

2023-12-28

Recruiting

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

NCT06129240Pulmonary Hypertension, Interstitial Lung Disease

Liquidia Technologies, Inc.

Observational

Arizona, California, Colorado, Connecticut, Florida, Indiana, Kentucky, Massachusetts

2023-12-28

Active, closed

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486Multiple Sclerosis

DrugFrexalimab

Sanofi

Phase 3

943

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2023-12-27

Recruiting

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

NCT06132035Age-related Wet Macular Degeneration

DrugsEylea·Aflibercept

Caregen Co. Ltd.

Phase 1

Connecticut, Florida, Georgia, Indiana, North Dakota, Pennsylvania

2023-12-22

Recruiting

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

NCT05280314Melanoma, Squamous Cell Carcinoma of Head and Neck

DrugsIO102-IO103·Pembrolizumab KEYTRUDA

IO Biotech

Phase 2

Connecticut, Massachusetts, Virginia

2023-12-21

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

1,264

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2023-12-21

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois

2023-12-18

Active, closed

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

NCT06111235Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma

DrugCretostimogene Grenadenorepvec

CG Oncology, Inc.

Phase 3

367

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2023-12-14

Active, closed

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473Multiple Sclerosis

DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab

Sanofi

Phase 3

1,655

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2023-12-13

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsNemtabrutinib·Ibrutinib·Acalabrutinib

Merck Sharp & Dohme LLC

Phase 3

1,200

Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Indiana

2023-12-13

Active, closed

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105GIST

DrugsRipretinib·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

California, Connecticut, Florida, Maryland, Massachusetts, Minnesota, New York, Ohio

2023-12-13

Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugNexiguran ziclumeran

Intellia Therapeutics

Phase 3

1,200

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois

2023-12-13

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130Advanced Solid Tumor

Eikon Therapeutics

Phase 1/2

156

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Michigan, Minnesota

2023-12-11

Active, closed

F15 Recharge Free Axonics SNM System Clinical Study

NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)

Axonics, Inc.

Not applicable

144

Connecticut, Florida, Georgia, Minnesota, Nebraska, New York, Oregon, South Carolina

2023-12-08

Active, closed

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05769153Neovascular Age-related Macular Degeneration (nAMD)

DrugAflibercept

Alcon Research

Phase 1/2

139

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2023-12-06

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia

2023-12-06

Recruiting

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT06072612Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic

DrugsRetifanlimab·Cyclophosphamide

BriaCell Therapeutics Corporation

Phase 3

404

Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas

2023-12-05

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716NASH With Fibrosis, MASH With Fibrosis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

1,650

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2023-12-01

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas

2023-11-29

By invitation

Evaluation of the GORE® Ascending Stent Graft

NCT05800743Aortic Aneurysm, Thoracic, Pseudoaneurysm, Aortic Dissection, Aorta; Lesion

W.L.Gore & Associates

Not applicable

370

Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois

2023-11-28

Recruiting

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

NCT06122077Lung Cancer Diagnosis

Freenome Holdings Inc.

Observational

20,000

California, Connecticut, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts

2023-11-28

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06031441Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors

DrugsTecentriq·Atezolizumab

Genentech, Inc.

Phase 1

Alabama, Connecticut, New York, Ohio, Pennsylvania, Tennessee

2023-11-27

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii

2023-11-23

By invitation

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

NCT06208878Hematologic Malignancy, Solid Malignancy

CRISPR Therapeutics AG

Observational

California, Connecticut, Georgia, Illinois, Kansas, Minnesota, Missouri, New York

2023-11-22

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois, Indiana

2023-11-21

Active, closed

SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

NCT06120205Hpv, HPV 16 Infection, HPV Infection, High Risk HPV

Teal Health, Inc.

Not applicable

870

Alabama, California, Colorado, Connecticut, Louisiana, Maryland, Massachusetts, Missouri

2023-11-20

Recruiting

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

NCT06143956Obesity, Overweight

DrugsMacupatide·Eloralintide·Mazdutide·Tirzepatide

Eli Lilly and Company

Phase 2

1,481

Arizona, California, Connecticut, Florida, Hawaii, Idaho, Illinois, Iowa

2023-11-17

Active, closed

The PEERLESS II Study

NCT06055920Pulmonary Embolism

Inari Medical

Not applicable

1,200

Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Michigan

2023-11-17

Active, closed

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Exemestane·Anastrozole·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

510

Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois

2023-11-16

Active, closed

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

NCT06292923Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences LTD

Phase 2

Connecticut, Maryland, Massachusetts, New York, Pennsylvania

2023-11-15

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

NCT06063967Crohn's Disease

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

289

Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana

2023-11-15

Active, closed

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms

DrugDisitamab Vedotin

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

120

Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan

2023-11-14

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Connecticut, Iowa, Missouri, Ohio, Wisconsin

2023-11-14

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Xeloda·Olaparib

AstraZeneca

Phase 3

1,902

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2023-11-14

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

NCT06107413Unresectable Metastatic Colorectal Cancer

DrugsFolinic acid·Telisotuzumab Adizutecan·Fluorouracil·Irinotecan

AbbVie

Phase 2

280

Arizona, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Louisiana

2023-11-12

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas

2023-11-08

Recruiting

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

NCT06086522Solid Tumor

Qualigen Theraputics, Inc.

Phase 1

Arizona, Connecticut, Michigan, Texas

2023-11-01

Recruiting

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

NCT05918211Single Ventricle Heart Disease

Mezzion Pharma Co. Ltd

Phase 3

436

Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida

2023-10-30

Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

1,600

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois

2023-10-26

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2023-10-25

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida

2023-10-25

Active, closed

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT05949684Myelodysplastic Syndromes

DrugsEpoetin Alfa·Reblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

402

California, Connecticut, Florida, Hawaii, Illinois, Indiana, Louisiana, Maryland

2023-10-24

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT06084936Lymphoma

DrugsGlofitamab·Bendamustine·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

182

California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Michigan, Missouri

2023-10-22

Active, closed

SELUTION 4 De Novo Small Vessel IDE Trial

NCT05946629Coronary Artery Disease

M.A. Med Alliance S.A.

Not applicable

960

Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii

2023-10-20

Recruiting

An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant

NCT05106387Chronic Kidney Disease (CKD)

DrugVonsetamig

Regeneron Pharmaceuticals

Observational

California, Connecticut, Illinois, Maryland, Minnesota, New York, Pennsylvania

2023-10-19

Active, closed

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

NCT05968326Adenocarcinoma, Pancreatic Ductal

DrugsAutogene cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab

Genentech, Inc.

Phase 2

260

California, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Michigan, Nebraska

2023-10-18

Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NCT05902988Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer

Volastra Therapeutics, Inc.

Phase 1/2

200

California, Colorado, Connecticut, Illinois, Indiana, Maryland, Michigan, New York

2023-10-18

Active, closed

Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR

NCT05295628Aortic Valve Stenosis, Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Valve Replacement

Emblok, Inc.

Not applicable

532

Arizona, California, Connecticut, District of Columbia, Illinois, Iowa, Kansas, Louisiana

2023-10-17

Active, closed

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806Multiple Myeloma

DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan

Celgene

Phase 3

California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan, Minnesota

2023-10-16

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444Chronic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

759

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2023-10-12

Active, closed

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756Arteriosclerosis, Hypercholesterolaemia

DrugsEnlicitide Decanoate·Enlicitide

Merck Sharp & Dohme LLC

Phase 3

14,550

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2023-10-09

Active, closed

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

NCT06082960Solid Tumors

DrugZimberelimab

Gilead Sciences

Phase 1

Connecticut, Tennessee, Texas

2023-10-09

By invitation

The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)

NCT06315023Peripheral Arterial Disease, Symptomatic Femoropopliteal Lesions

Endologix

Observational

450

California, Connecticut, District of Columbia, Florida, Massachusetts, Missouri, New York, Ohio

2023-10-06

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida

2023-10-05

Active, closed

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

106

California, Connecticut, Florida, Kansas, Kentucky, Michigan, Missouri, New Jersey

2023-10-05

Recruiting

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

NCT05918861Acute Coronary Syndrome

DalCor Pharmaceuticals

Phase 3

2,000

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia

2023-10-03

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457Episodic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

751

Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Maryland

2023-09-29

Active, closed

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

NCT05923866Multiple System Atrophy (MSA)

Ono Pharmaceutical Co., Ltd.

Phase 2

California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Michigan

2023-09-22

Recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

NCT05981703Advanced Solid Tumor, Solid Tumor

DrugTislelizumab

BeOne Medicines

Phase 1

337

California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas

2023-09-21

Active, closed

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

NCT06037252Type 2 Diabetes, Obesity

DrugTirzepatide

Eli Lilly and Company

Phase 2

414

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana

2023-09-21

Active, closed

Aventus Thrombectomy System Pulmonary Embolism Clinical Study

NCT05907564Pulmonary Embolism, Embolism, Embolism and Thrombosis, Vascular Diseases

Inquis Medical, Inc.

Not applicable

120

Arizona, California, Connecticut, District of Columbia, Georgia, Illinois, Indiana, Louisiana

2023-09-20

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Alaska, California, Colorado, Connecticut, District of Columbia, Florida, Hawaii, Illinois

2023-09-18

Active, closed

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

NCT05904886Hepatocellular Carcinoma

DrugsTiragolumab·Tecentriq·Avastin·Atezolizumab

Hoffmann-La Roche

Phase 3

687

Arkansas, California, Connecticut, District of Columbia, Florida, Illinois, Kentucky, Louisiana

2023-09-14

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida

2023-09-14

By invitation

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy

NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis

DrugEfgartigimod PH20

argenx

Phase 3

240

Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, New York

2023-09-12

Active, closed

A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

NCT06018428Alopecia Areata

DrugBempikibart

Q32 Bio Inc.

Phase 2

Arizona, Arkansas, California, Connecticut, Florida, Indiana, Kentucky, Massachusetts

2023-09-12

Active, closed

To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

NCT05908084End Stage Renal Disease (ESRD)

Humacyte, Inc.

Phase 3

121

Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Maryland

2023-09-07

Recruiting

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06040541Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors

DrugsRMC-9805·Cetuximab

Revolution Medicines, Inc.

Phase 1

604

California, Connecticut, Florida, Maryland, Massachusetts, New York, North Carolina, Ohio

2023-09-07

Recruiting

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

NCT05652686Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

DrugsLurbinectedin·Topotecan·Irinotecan·Etoposide

Phanes Therapeutics

Phase 1/2

203

California, Colorado, Connecticut, Maryland, Massachusetts, Missouri, North Carolina, Oklahoma

2023-09-05

Active, closed

Enlighten Study: The EV-ICD Post Approval Registry

NCT06048731Ventricular Arrhythmia, Tachycardia

Medtronic

Observational

1,000

California, Connecticut, Florida, Georgia, Indiana, Iowa, Kentucky, Maryland

2023-09-01

Active, closed

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 3

500

Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois

2023-08-31

Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

NCT06270706Advanced or Metastatic Solid Tumor

DrugPembrolizumab

Pliant Therapeutics, Inc.

Phase 1

124

Connecticut, Georgia, Michigan, Missouri, New Jersey, New York, North Carolina, South Dakota

2023-08-30

Recruiting

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT05798923Pulmonary Hypertension Due to Lung Diseases and Hypoxia

OrphAI Therapeutics

Phase 2

Alabama, Arizona, Colorado, Connecticut, Florida, Massachusetts, Minnesota, Nebraska

2023-08-30

Recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT05867251Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification

DrugsAVZO-021·Sacituzumab Govitecan·Abemaciclib·Ribociclib

Avenzo Therapeutics, Inc.

Phase 1/2

430

Connecticut, Florida, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Texas

2023-08-30

Recruiting

US National OCS Heart Perfusion (OHP) Registry

NCT05915299Heart Transplant

TransMedics

Observational

100,000

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky

2023-08-25

Active, closed

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

NCT05929235Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label

DrugsKeytruda·Pembrolizumab

Flare Therapeutics Inc.

Phase 1

120

California, Connecticut, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio

2023-08-24

Active, closed

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

NCT05907304Advanced or Metastatic Solid Tumors

DrugsNaporafenib·Trametinib

Erasca, Inc.

Phase 1

California, Connecticut, Florida, Georgia, Michigan, Missouri, Nevada, Oregon

2023-08-17

Active, closed

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT05996471HIV Infections

DrugsVH3810109·Phesgo·Cabotegravir

ViiV Healthcare

Phase 2

185

Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Massachusetts

2023-08-17

Active, closed

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

NCT06021522Tourette Syndrome

Emalex Biosciences Inc.

Phase 3

150

Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Illinois

2023-08-16

Recruiting

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

NCT05803941Prostate Cancer

DrugLu-PSMA

Novartis Pharmaceuticals

Phase 4

700

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana

2023-08-14

Recruiting

Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

NCT03463954Malignant Neoplasm of Breast

Novian Health Inc.

Not applicable

122

California, Connecticut, Maryland, New Jersey, New York

2023-08-09

Recruiting

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer

DrugIza-bren

SystImmune Inc.

Phase 1

540

California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa, Kentucky

2023-08-08

Active, closed

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

NCT05800015Non-small Cell Lung Cancer

DrugsFianlimab·Cemiplimab·Paraplatin·Pemetrexed

Regeneron Pharmaceuticals

Phase 2/3

160

Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Mississippi

2023-08-08

Recruiting

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

NCT05855200Colonic Neoplasms, Neoplasms, Colon

DrugsCapeox·Dostarlimab·Folfox

GlaxoSmithKline

Phase 3

892

Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas

2023-08-01

Recruiting

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

NCT05762107Type 1 Diabetes Mellitus With Hypoglycemia

Zucara Therapeutics Inc.

Phase 2

186

Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois

2023-07-28

Active, closed

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643Systemic Lupus Erythematosus

DrugUpadacitinib

AbbVie

Phase 3

1,014

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois

2023-07-25

Active, closed

Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

NCT05910528Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 2

Alabama, Connecticut, Florida, Massachusetts, Michigan

2023-07-24

Recruiting

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

NCT05974150Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer

Carevive Systems, Inc.

Observational

Connecticut, Illinois, North Carolina, Ohio

2023-07-19

Active, closed

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,089

Arkansas, California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts

2023-07-19

Recruiting

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

NCT05735184Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1

DrugsQuizartinib·Ziftomenib·Venclyxto·Daunorubicin

Kura Oncology, Inc.

Phase 1

420

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa

2023-07-18

Recruiting

A Validation Study to Evaluate the Performance of Caption Health Lung Guidance and Interpretation

NCT05992324Shortness of Breath

Caption Health, Inc.

Not applicable

220

Connecticut, Illinois, North Carolina

2023-07-17

Active, closed

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

NCT05968430Hypertension

Mineralys Therapeutics Inc.

Phase 3

1,076

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho

2023-07-14

Recruiting

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

NCT05808634Advanced Adenocarcinoma

BioAtla, Inc.

Phase 1

168

California, Connecticut, Illinois, Michigan, Ohio, Washington

2023-07-14

Recruiting

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1,000

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2023-07-11

Active, closed

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

NCT05726227Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 3

210

California, Connecticut, Georgia, Idaho, Louisiana, Maryland, Massachusetts, Minnesota

2023-07-07

Active, closed

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05785767Advanced Non-Small Cell Lung Cancer

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2/3

149

Arizona, California, Connecticut, Florida, Illinois, Louisiana, Mississippi, Missouri

2023-06-30

Active, closed

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510Non Small Cell Lung Cancer

DrugsGotistobart·Taxotere·Docetaxel

OncoC4, Inc.

Phase 3

630

Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Kansas

2023-06-28

Recruiting

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

NCT05785754Advanced or Metastatic Solid Tumors

DrugsDCSZ11·Tebentafusp·Doxorubicin·Pembrolizumab

DynamiCure Biotechnology

Phase 1

320

Alabama, Arizona, Colorado, Connecticut, Florida, Maryland, Massachusetts, Minnesota

2023-06-28

Active, closed

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

NCT05531656Early Alzheimer's Disease

Cognition Therapeutics

Phase 2

540

Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Indiana

2023-06-28

Active, closed

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

NCT05812027Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers

TScan Therapeutics, Inc.

Observational

1,150

Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota

2023-06-26

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho

2023-06-21

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082Non-Small Cell Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 1/2

320

California, Connecticut, Florida, New York, Texas, Virginia

2023-06-20

Active, closed

Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta

NCT05768854Osteogenesis Imperfecta

DrugSetrusumab

Ultragenyx Pharmaceutical Inc

Phase 3

Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois

2023-06-14

Recruiting

A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

NCT05865535Cachexia

AVEO Pharmaceuticals, Inc.

Phase 1

California, Connecticut, Florida, Nebraska, New Jersey, New York, Oregon, South Carolina

2023-06-13

Recruiting

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

NCT05897320Episodic Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

315

Connecticut, Florida, Georgia, Kentucky, Maryland, Michigan, New York, North Carolina

2023-06-08

Recruiting

Study of ALTO-300 in MDD

NCT05922878Major Depressive Disorder

Alto Neuroscience

Phase 2

321

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho

2023-06-08

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862Breast Cancer

DrugsBupropion·Omeprazole·Alpelisib·Inavolisib

Hoffmann-La Roche

Phase 3

420

California, Colorado, Connecticut, Florida, Georgia, Kentucky, Massachusetts, Michigan

2023-06-07

Active, closed

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

NCT05888831Advanced Solid Tumors

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 1/2

100

California, Connecticut, New Jersey, New York

2023-06-06

Recruiting

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3

DrugSafusidenib

Nuvation Bio Inc.

Phase 3

365

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2023-06-05

Active, closed

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

NCT05889273Autism Spectrum Disorder

MapLight Therapeutics

Phase 2

120

Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri

2023-06-01

Recruiting

Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence

NCT05972070Myocardial Infarction, Percutaneous Transluminal Coronary Angioplasty, Coronary Artery Bypass, Stable Angina

ROM Technologies, INC

Observational

500

Connecticut

2023-06-01

Active, closed

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

398

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Illinois, Indiana

2023-06-01

Recruiting

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture

NCT05883241Bone Fracture, Fresh Fracture

DrugDiclofenac

ZetrOZ, Inc.

Phase 1

Connecticut, Virginia

2023-06-01

Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor

DrugsLonsurf·MFOLFOX6·Trifluridine/Tipiracil·Avastin

Parabilis Medicines, Inc.

Phase 1/2

619

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Maryland, Massachusetts

2023-05-23

Active, closed

Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease

NCT05894343Parkinson's Disease

MeiraGTx, LLC

Phase 1/2

Connecticut, Michigan, New York, Pennsylvania, West Virginia

2023-05-19

Active, closed

Assessment of Combined CCM and ICD Device in HFrEF

NCT05855135Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy

Impulse Dynamics

Not applicable

300

Arizona, California, Connecticut, Florida, Iowa, Kansas, Kentucky, Massachusetts

2023-05-17

Active, closed

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

NCT05729568HIV-1 Infection

DrugsTeropavimab·Zinlirvimab·Lenacapavir

Gilead Sciences

Phase 2

California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Missouri, New Mexico

2023-05-15

Recruiting

XTX301 in Patients With Advanced Solid Tumors

NCT05684965Advanced Solid Tumor

Xilio Development, Inc.

Phase 1/2

358

California, Connecticut, Minnesota, Missouri, New Jersey, Ohio, Pennsylvania, Texas

2023-05-11

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas, Louisiana

2023-05-08

Active, closed

Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

NCT05755711Coronary Artery Disease

Shockwave Medical, Inc.

Observational

399

California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas, Louisiana

2023-05-03

Active, closed

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis

DrugDupilumab

Regeneron Pharmaceuticals

Phase 2

Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas, Massachusetts

2023-05-03

Recruiting

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05850689Major Depressive Disorder

DrugLumateperone

Intra-Cellular Therapies, Inc.

Phase 3

470

Alabama, California, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri

2023-05-02

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer

Genentech, Inc.

Phase 1

210

Arizona, Connecticut, Florida, Illinois, Texas

2023-05-02

Recruiting

Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)

NCT05765175Tachycardia, Ventricular

Varian, a Siemens Healthineers Company

Not applicable

380

California, Connecticut, Massachusetts, Minnesota, Missouri, Ohio, Pennsylvania, South Carolina

2023-04-21

Active, closed

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer

DrugsKeytruda·Pembrolizumab

IDEAYA Biosciences

Phase 1

216

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana

2023-04-18

Recruiting

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139Breast Cancer, Solid Tumors, Adult

DrugsTersolisib·Imlunestrant·Tamoxifen·Exemestane

Eli Lilly and Company

Phase 1/2

880

California, Colorado, Connecticut, Florida, Georgia, Iowa, Louisiana, Massachusetts

2023-04-17

Active, closed

Study to Evaluate the Safety and Effectiveness of GP0116

NCT05987163Skin Manifestations

Galderma R&D

Not applicable

186

California, Connecticut, Florida, Georgia, Louisiana, Massachusetts, Michigan, New York

2023-04-12

Recruiting

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

NCT05555589Neurotrophic Keratopathy

ReGenTree, LLC

Phase 3

California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky

2023-04-11

Active, closed

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

NCT05757869Atrial Fibrillation

DrugsMilvexian·Apixaban

Janssen Research & Development, LLC

Phase 3

20,284

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia

2023-04-11

Active, closed

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma

AbbVie

Phase 1

California, Connecticut, Florida, Indiana, Louisiana, Michigan, New York, North Carolina

2023-04-04

Active, closed

A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

NCT03862430Glioblastoma Multiforme

NuvOx LLC

Phase 2

Arizona, California, Connecticut, Illinois, Louisiana, Missouri, New Jersey, North Carolina

2023-03-31

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida

2023-03-31

Active, closed

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515Relapsed or Refractory Multiple Myeloma

DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib

Janssen Research & Development, LLC

Phase 3

614

Alaska, Arizona, California, Colorado, Connecticut, Florida, Iowa, Louisiana

2023-03-29

Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

NCT05669430Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma

DrugsGV20-0251·Keytruda·Pembrolizumab

GV20 Therapeutics

Phase 1/2

365

California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Michigan, New York

2023-03-23

Active, closed

Thoraflex Hybrid and Relay Extension Post-Approval Study

NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm

Vascutek Ltd.

Observational

352

Alabama, California, Colorado, Connecticut, District of Columbia, Illinois, Indiana, Maryland

2023-03-17

Recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT05719558Advanced Solid Tumors

DrugsRamucirumab·Trifluridine/Tipiracil·Fluorouracil·Leucovorin

Astellas Pharma Global Development, Inc.

Phase 1

798

Connecticut, Florida, Iowa, Kentucky, Michigan, Minnesota, New York, Ohio

2023-03-13

Active, closed

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

14,012

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii

2023-03-09

By invitation

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05735483Atopic Dermatitis, Eczema

DrugLebrikizumab

Eli Lilly and Company

Phase 3

333

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois

2023-03-09

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

California, Connecticut, Florida, Illinois, Kentucky, Louisiana, Mississippi, Missouri

2023-03-03

Active, closed

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

NCT05489588Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis

W.L.Gore & Associates

Not applicable

165

California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Michigan, New Jersey

2023-03-02

Active, closed

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

NCT05639114Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

436

Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana

2023-03-02

Active, closed

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

NCT05669755Cardiovascular Disease

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

7,101

Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois

2023-03-01

Recruiting

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases

DrugBaricitinib

Eli Lilly and Company

Phase 3

595

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana

2023-02-27

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2023-02-27

Recruiting

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

NCT05471856Solid Tumors

DrugEzabenlimab

Boehringer Ingelheim

Phase 1

California, Connecticut, New Jersey

2023-02-24

Recruiting

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors

Fore Biotherapeutics

Phase 2

254

California, Connecticut, Florida, Maryland, Massachusetts, Minnesota, Missouri, Nebraska

2023-02-21

Active, closed

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034Ischemic Stroke; Ischemic Attack, Transient

DrugMilvexian

Janssen Research & Development, LLC

Phase 3

12,523

Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2023-02-15

Active, closed

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

NCT05478304Ischemic Stroke, Systemic Embolism

AtriCure, Inc.

Not applicable

6,573

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia

2023-01-25

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

NCT05580562H3 K27M, Glioma

DrugDordaviprone

Jazz Pharmaceuticals

Phase 3

510

Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois

2023-01-23

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2023-01-16

Active, closed

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT05617677Systemic Lupus Erythematosus

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

516

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2023-01-12

Recruiting

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

DrugsElacestrant·Exemestane·Everolimus·Abemaciclib

Ellipses Pharma

Phase 1/2

Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas, Virginia

2023-01-11

Recruiting

Alleviant ALLAY-HF Study

NCT05685303Heart Failure

Alleviant Medical, Inc.

Not applicable

700

Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky

2023-01-10

Recruiting

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

NCT05701917Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome

Inari Medical

Not applicable

300

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana

2023-01-06

Recruiting

Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial

NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)

Medtronic Cardiovascular

Not applicable

600

California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas

2023-01-05

Active, closed

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

NCT05653882Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck

DrugsEtakafusp alfa·Keytruda·Pembrolizumab

Asher Biotherapeutics, Inc.

Phase 1

552

California, Connecticut, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey

2023-01-04

Active, closed

SpermQT Prospective Observational Trial

NCT05966883Male Infertility

Inherent Biosciences

Observational

1,000

California, Colorado, Connecticut, Massachusetts, Texas, Washington

2023-01-01

Active, closed

A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.

NCT05627362Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen

Phase 2

California, Colorado, Connecticut, Florida, Georgia, Louisiana, Maryland, Massachusetts

2022-12-29

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2022-12-27

Active, closed

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

NCT05446298Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

DrugsGotistobart·Keytruda·Pembrolizumab

OncoC4, Inc.

Phase 2

Arizona, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana, Minnesota

2022-12-22

Recruiting

PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

NCT05313165Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease

LimFlow, Inc.

Not applicable

100

California, Connecticut, Florida, Illinois, Massachusetts, Missouri, New Hampshire, New Jersey

2022-12-22

Active, closed

First in Human Study of AZD9592 in Solid Tumors

NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

DrugsAZD9592·Osimertinib·Leucovorin·Adrucil

AstraZeneca

Phase 1

190

California, Connecticut, District of Columbia, Illinois, Maryland, Massachusetts, New York, Pennsylvania

2022-12-21

Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916Breast Cancer

Greenwich LifeSciences, Inc.

Phase 3

2,250

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2022-12-16

Recruiting

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

NCT05768932Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)

SillaJen, Inc.

Phase 1

260

Connecticut, Florida, Georgia, Michigan, New York, Oregon, Texas

2022-12-14

Active, closed

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303Atherosclerotic Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

7,297

Alabama, Alaska, Arizona, California, Colorado, Connecticut, District of Columbia, Florida

2022-12-14

Recruiting

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229Primary Mitochondrial Disease

DrugNapazimone

Pharming Technologies B.V.

Phase 2

180

California, Colorado, Connecticut, Florida, Georgia, Indiana, Maryland, Minnesota

2022-12-13

Active, closed

(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds

NCT05364502Arterial Bleeding in Solid Organs and Peripheral Arteries

Instylla, Inc.

Not applicable

130

Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Indiana, Maryland

2022-12-12

Active, closed

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

NCT05529316Advanced Melanoma

DrugsBalstilimab·Botensilimab

Agenus Inc.

Phase 2

150

Arizona, California, Connecticut, District of Columbia, Massachusetts, New Jersey

2022-12-12

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654Triple Negative Breast Cancer

DrugsXeloda·Sacituzumab Govitecan·Keytruda·Capecitabine

Gilead Sciences

Phase 3

1,514

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2022-12-12

Active, closed

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

696

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2022-12-09

Active, closed

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886Breast Cancer

DrugsGedatolisib·Alpelisib·Palbociclib·Fulvestrant

Celcuity Inc

Phase 3

701

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois

2022-12-08

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

NCT05599984Advanced Solid Tumors

DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin

AbbVie

Phase 1

288

Arizona, California, Connecticut, District of Columbia, Illinois, Indiana, Iowa, Michigan

2022-12-05

Active, closed

SELUTION4SFA Trial

NCT05132361Peripheral Arterial Disease, Superficial Femoral Artery Stenosis

M.A. Med Alliance S.A.

Not applicable

300

Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana

2022-12-01

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida

2022-11-28

Active, closed

A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.

NCT05295290Myocarditis

Pfizer

Phase 4

319

California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Louisiana, Massachusetts

2022-11-21

Active, closed

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

NCT05384587Chronic Myelogenous Leukemia - Chronic Phase

DrugsAsciminib·ABL001

Novartis Pharmaceuticals

Phase 2

Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia

2022-11-11

Active, closed

REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /

NCT05372679Uncontrolled Stage 2 Hypertension

SoniVie Inc.

Not applicable

Alabama, Arkansas, Connecticut, Illinois, Minnesota, New York, North Carolina, South Carolina

2022-11-11

Active, closed

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

NCT05490446Myelodysplastic Syndromes

DrugTebapivat

Agios Pharmaceuticals, Inc.

Phase 2

California, Connecticut, Florida, Illinois, Missouri, New York, North Carolina

2022-11-07

Active, closed

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)

NCT05473910AML, MDS

DrugTSC-101

TScan Therapeutics, Inc.

Phase 1

310

California, Colorado, Connecticut, Florida, Georgia, Maryland, Massachusetts, Michigan

2022-11-01

Active, closed

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

NCT05397639Agitation, Alzheimer's Type Dementia

Suven Life Sciences Limited

Phase 3

375

California, Connecticut, Florida, Illinois, New Jersey, New York, Ohio, South Carolina

2022-11-01

Recruiting

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941Pneumonia

Pfizer

Observational

12,500

California, Connecticut, District of Columbia, Georgia, Kentucky, Louisiana, Maryland, Massachusetts

2022-10-27

Active, closed

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

NCT05284747Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization

DrugsRepatha·Evolocumab

Amgen

Phase 4

6,019

Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois

2022-10-26

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa

2022-10-25

Active, closed

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510Pulmonary Arterial Hypertension

DrugTreprostinil

United Therapeutics

Phase 4

Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Massachusetts

2022-10-20

Active, closed

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05559359Atopic Dermatitis, Eczema

DrugLebrikizumab

Eli Lilly and Company

Phase 3

377

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Idaho, Illinois

2022-10-18

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Arizona, Arkansas, Connecticut, District of Columbia, Florida, Illinois, Kansas, Louisiana

2022-10-13

Active, closed

Study of Oral MRT-2359 in Selected Cancer Patients

NCT05546268NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL

DrugMRT-2359

Monte Rosa Therapeutics, Inc

Phase 1/2

174

Arizona, California, Connecticut, Kansas, Massachusetts, Michigan, Missouri, New York

2022-10-12

Active, closed

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

NCT05556512Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

15,374

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii

2022-10-11

Active, closed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054Breast Neoplasms

DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole

Eli Lilly and Company

Phase 3

8,000

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2022-10-04

Active, closed

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

NCT05482971Essential Thrombocythemia

DrugBesremi

PharmaEssentia

Phase 2

Alabama, California, Connecticut, District of Columbia, Georgia, Indiana, Kentucky, Louisiana

2022-09-29

Active, closed

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

DrugsMIRV·Mirvetuximab Soravtansine·Carboplatin

AbbVie

Phase 2

125

Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Massachusetts

2022-09-28

Active, closed

A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease

DrugGuselkumab

Janssen-Cilag Ltd.

Phase 3

288

Alabama, Connecticut, Florida, Kansas, Kentucky, Missouri, New York, Oklahoma

2022-09-27

Recruiting

A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

NCT05431088Sickle Cell Disease

Pfizer

Phase 2/3

389

Alabama, Connecticut, Florida, Georgia, Illinois, Louisiana, Michigan, Mississippi

2022-09-22

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

California, Colorado, Connecticut, Florida, Georgia, Kansas, Louisiana, Maryland

2022-09-20

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana

2022-09-19

Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

NCT05519449Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer

DrugsJANX007·Darolutamide

Janux Therapeutics

Phase 1

272

Alabama, Arizona, California, Connecticut, Florida, Illinois, Maryland, Minnesota

2022-09-15

Active, closed

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

NCT05425940Colorectal Cancer

DrugsZanzalintinib·Regorafenib·Tecentriq·Atezolizumab

Exelixis

Phase 3

901

Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana

2022-09-07

Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

NCT05548296Endometrial Adenocarcinoma

DrugGemcitabine

Acrivon Therapeutics

Phase 2

350

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida

2022-08-29

Recruiting

A Prospective Sub-Study of the Global Hypophosphatasia Registry

NCT05234567Hypophosphatasia

DrugAsfotase alfa

Alexion Pharmaceuticals, Inc.

Observational

Connecticut, Illinois, Massachusetts, Missouri, New York, Ohio, Pennsylvania, Tennessee

2022-08-25

Recruiting

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

410

Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, New York

2022-08-23

Active, closed

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

NCT05536973Neovascular Age-related Macular Degeneration

Adverum Biotechnologies, Inc.

Phase 2

Arizona, California, Colorado, Connecticut, Florida, Hawaii, Michigan, Mississippi

2022-08-23

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2022-08-22

Active, closed

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

NCT05451810Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma

DrugEpcoritamab

Genmab

Phase 2

184

Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2022-08-17

Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705Obstructive Hypertrophic Cardiomyopathy

DrugMavacamten

Bristol-Myers Squibb

Observational

1,700

Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2022-08-16

Active, closed

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341HIV-1-infection

DrugsBictegravir·Lenacapavir

Gilead Sciences

Phase 2/3

689

California, Colorado, Connecticut, Florida, Georgia, Illinois, Missouri, New Jersey

2022-08-16

Active, closed

MiSight 1 Day Safety Post-Approval Study

NCT05285527Myopia

CooperVision, Inc.

Not applicable

2,400

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Indiana

2022-08-15

Active, closed

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT

NCT04858776Iliofemoral; Thrombosis

Mercator MedSystems, Inc.

Phase 2

Connecticut, Florida, Illinois, Louisiana, Maryland, New York, North Carolina, Ohio

2022-08-08

Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV

DrugsAbraxane·Nab-paclitaxel·Gemcitabine

Panbela Therapeutics, Inc.

Phase 2/3

600

Arkansas, California, Connecticut, District of Columbia, Michigan, Minnesota, New York, Ohio

2022-08-08

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Tamoxifen·Exemestane·Everolimus

Genentech, Inc.

Phase 3

373

Alaska, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois

2022-08-03

Active, closed

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

NCT05092347Chronic Kidney Disease (CKD)

DrugVonsetamig

Regeneron Pharmaceuticals

Phase 1/2

California, Connecticut, District of Columbia, Illinois, Maryland, Minnesota, New York, Pennsylvania

2022-08-02

Active, closed

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

NCT05433584Type 2 Diabetes

DrugTirzepatide

Eli Lilly and Company

Phase 4

780

Alabama, California, Connecticut, Florida, Georgia, Indiana, Iowa, Kentucky

2022-08-01

Active, closed

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Triple Negative Breast Cancer, PD-L1 Positive

DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel

Gilead Sciences

Phase 3

443

Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2022-07-25

Active, closed

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT05321420Idiopathic Pulmonary Fibrosis

DrugsDeupirfenidone·Pirfenidone

PureTech

Phase 2

240

Alabama, California, Connecticut, Florida, Georgia, Indiana, Kansas, North Carolina

2022-07-22

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471Crohn's Disease

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

703

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2022-07-22

Recruiting

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

NCT06426628Pulmonary Nodule, Solitary, Lung Cancer

Veracyte, Inc.

Observational

2,400

Connecticut, Florida, Illinois, Kansas, Kentucky, Louisiana, Maryland, Massachusetts

2022-07-18

Recruiting

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

NCT05475925LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma

DrugDibotatug

Dren Bio

Phase 1/2

200

Alabama, California, Connecticut, Florida, Massachusetts, New York, Ohio, Pennsylvania

2022-07-13

Active, closed

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446Coronary Artery Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

610

Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Illinois, Indiana

2022-07-08

Active, closed

Study of INCB123667 in Subjects With Advanced Solid Tumors

NCT05238922Solid Tumors

DrugsRibociclib·Palbociclib·Olaparib·Fulvestrant

Incyte Corporation

Phase 1

291

California, Colorado, Connecticut, Florida, Georgia, New York, North Carolina, Pennsylvania

2022-07-05

By invitation

Pre-hospital Ventilation Clinical Study

NCT05604430Altered Mental Status, Sepsis, Heart Failure, Hemorrhage

Zoll Medical Corporation

Observational

500

Connecticut, Louisiana, Massachusetts, Texas, Washington

2022-06-30

Recruiting

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

NCT05303064Schizophrenia, Bipolar I Disorder

DrugsOLZ/SAM·Olanzapine

Alkermes, Inc.

Phase 3

220

Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2022-06-30

Active, closed

Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma

NCT05226494Glioma, Malignant

NanoPharmaceuticals LLC

Phase 1

Connecticut

2022-06-23

Active, closed

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997Multiple Myeloma

DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone

Celgene

Phase 3

939

Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky

2022-06-23

Recruiting

GEMINI-NSCLC: NSCLC Biomarker Study

NCT05236114Non-Small Cell Lung Cancer

Tempus AI

Observational

1,200

Alabama, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois

2022-06-22

Recruiting

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

NCT05172960Aortic Stenosis, Severe

Edwards Lifesciences

Not applicable

1,234

California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas

2022-06-20

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720Non-Hodgkin Lymphoma

DrugsGolcadomide·Epcoritamab·Polatuzumab Vedotin·Doxorubicin Hydrochloride

Genmab

Phase 2

264

Arizona, Connecticut, Delaware, Florida, Georgia, Maryland, Missouri, New York

2022-06-14

Recruiting

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

NCT05433142Clear Cell Renal Cell Carcinoma

Xencor, Inc.

Phase 1

307

Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Minnesota

2022-06-13

Active, closed

MOTIV BTK Randomized Controlled Trial

NCT05406622Critical Limb Ischemia

REVA Medical, Inc.

Not applicable

292

California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Iowa

2022-06-10

Active, closed

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

NCT05329766Gastrointestinal Tract Malignancies

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Fluorouracil

Arcus Biosciences, Inc.

Phase 2

332

Arizona, California, Connecticut, Florida, Massachusetts, New York, North Carolina, Ohio

2022-06-10

Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559Solid Tumor

DrugsNanoparticle albumin-bound-paclitaxel·Setidegrasib·Liposomal Irinotecan·Fluorouracil

Astellas Pharma Inc

Phase 1

681

California, Colorado, Connecticut, District of Columbia, Florida, Kansas, Massachusetts, Michigan

2022-06-08

Active, closed

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

NCT05428969Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML

DrugsBexmarilimab·Venclyxto·Azacitidine·Venetoclax

Faron Pharmaceuticals Ltd

Phase 1/2

181

California, Connecticut, North Carolina, Texas

2022-06-02

Active, closed

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

NCT05095727Glycogen Storage Disease

ModernaTX, Inc.

Phase 1/2

Connecticut, Massachusetts, North Carolina, Ohio, Pennsylvania, Texas, Utah

2022-06-01

Active, closed

HEAL-IST IDE Trial

NCT05280093Inappropriate Sinus Tachycardia

AtriCure, Inc.

Not applicable

142

Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Kansas

2022-05-31

Recruiting

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175Colitis, Ulcerative

DrugOzanimod

Bristol-Myers Squibb

Phase 2/3

120

Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana

2022-05-30

Active, closed

PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

NCT05174767Acute Aortic Dissection

Artivion Inc.

Not applicable

115

Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts

2022-05-27

Recruiting

SELUTION4BTK Trial

NCT05055297Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities

M.A. Med Alliance S.A.

Not applicable

376

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois

2022-05-19

Active, closed

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257Limited-Stage Small Cell Lung Cancer

DrugsCarboplatin/cisplatin-etoposide·Slulimumab·Serplulimab

Shanghai Henlius Biotech

Phase 3

511

California, Colorado, Connecticut, Florida, Kansas, Louisiana, Minnesota, Nevada

2022-05-17

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Kentucky, Michigan

2022-05-16

By invitation

Posterior Cervical Fixation Study

NCT04770571Degenerative Disc Disease, Craniocervical Injuries, Cervical Radiculopathy, Cervical Disc Disease

NuVasive

Observational

150

California, Connecticut, Maryland, New York, Pennsylvania, Tennessee, Texas

2022-05-10

Active, closed

RADIANCE Continued Access Protocol

NCT05017935Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases

ReCor Medical, Inc.

Not applicable

300

California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Louisiana

2022-05-04

Active, closed

STOP AF First Post-Approval Study

NCT05227053Paroxysmal Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

200

Alaska, Connecticut, District of Columbia, Florida, Iowa, Massachusetts, Michigan, Ohio

2022-04-28

Active, closed

Evolut™ EXPAND TAVR II Pivotal Trial

NCT05149755Moderate Aortic Valve Stenosis

Medtronic Cardiovascular

Not applicable

650

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Kentucky

2022-04-27

Active, closed

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

NCT05232838Hydrocephalus, Normal Pressure, Hydrocephalus

CereVasc Inc

Not applicable

Connecticut, Florida, Kansas, Kentucky, Massachusetts, New York, Rhode Island, Virginia

2022-04-20

Active, closed

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

NCT05222906Gaucher's Disease Type III

DrugsImiglucerase·Venglustat

Sanofi

Phase 3

Connecticut, Iowa, Texas, Virginia

2022-04-18

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550Non-small Cell Lung Cancer

DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab

AstraZeneca

Phase 2

630

Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts

2022-04-14

Active, closed

CONVERGE Post-Approval Study (PAS)

NCT05393180Chronic Atrial Fibrillation

AtriCure, Inc.

Not applicable

California, Connecticut, Florida, Georgia, Kentucky, Maryland, Massachusetts, New Jersey

2022-04-13

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)

DrugBexobrutideg

Nurix Therapeutics, Inc.

Phase 1

572

California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland, New York

2022-04-13

Recruiting

Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System

NCT05406167Cancer, Cancer Central Nervous System, Cancer Thoracic, Cancer, Gastrointestinal

RefleXion Medical

Observational

500

California, Connecticut, Pennsylvania, Texas

2022-04-12

Recruiting

Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry

NCT04829175Stress Urinary Incontinence, Pelvic Organ Prolapse

Ethicon, Inc.

Observational

1,000

Connecticut, North Carolina, Pennsylvania

2022-04-11

Active, closed

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

NCT05071716Hepatic Encephalopathy

DrugRifaximin SSD

Bausch Health Americas, Inc.

Phase 3

524

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2022-04-07

Active, closed

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

NCT05306288Lung Cancer

Delfi Diagnostics Inc.

Observational

11,935

Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky

2022-04-07

Active, closed

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

NCT05210790Polycythemia Vera

DrugRusfertide

Protagonist Therapeutics, Inc.

Phase 3

293

Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana

2022-04-01

Recruiting

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

NCT05312879Proteinuric Kidney Disease

Vertex Pharmaceuticals Incorporated

Phase 2/3

466

Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia

2022-03-30

Active, closed

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease

DrugTulisokibart

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

154

Arizona, California, Colorado, Connecticut, District of Columbia, Maryland, Massachusetts, Michigan

2022-03-29

Active, closed

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

NCT05477576GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors

DrugsRYZ101·Octreotide·Lanreotide·Sunitinib

RayzeBio, Inc.

Phase 3

343

Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Iowa, Kentucky

2022-03-24

Recruiting

OssDsign® Spine Registry Study ("Propel")

NCT05329129Degenerative Disc Disease, Spinal Stenosis

OssDsign

Observational

450

California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland, Minnesota

2022-03-23

Active, closed

R&D Study to Evaluate Cordio's Usability and to Collect Patient Speech Utterances

NCT05876533Chronic Heart Failure

Cordio Medical

Observational

216

Connecticut, Florida, Georgia

2022-03-18

Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

NCT05315700Solid Tumors

ORIC Pharmaceuticals

Phase 1/2

350

California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York

2022-03-10

Active, closed

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

NCT05250973Amyloidosis

DrugsBortezomib·Daratumumab·Dexamethasone·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

151

California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York, North Carolina

2022-03-01

Active, closed

Setrusumab vs Placebo for Osteogenesis Imperfecta

NCT05125809Osteogenesis Imperfecta

DrugSetrusumab

Ultragenyx Pharmaceutical Inc

Phase 2/3

183

Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois

2022-02-21

Recruiting

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05128825High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

DrugAzenosertib

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 2

310

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois

2022-02-17

Active, closed

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

NCT05141721Colorectal Neoplasms

DrugsFluoropyrimidine·Yervoy·Tecentriq·Avastin

Seattle Project Corporation

Phase 2/3

700

Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Indiana

2022-02-12

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

NCT05031780Sickle Cell Disease

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 2/3

286

California, Connecticut, District of Columbia, Florida, Illinois, Indiana, Louisiana, Maryland

2022-02-11

Active, closed

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

NCT05202509Atherosclerotic Cardiovascular Disease

DrugObicetrapib

NewAmsterdam Pharma

Phase 3

9,541

Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois

2022-02-07

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan

2022-02-07

Recruiting

Assessment of CCM in HF With Higher Ejection Fraction

NCT05064709Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction

Impulse Dynamics

Not applicable

1,500

Alabama, Arizona, California, Connecticut, Florida, Georgia, Indiana, Iowa

2022-02-03

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky

2022-02-03

Active, closed

Tumor-induced Osteomalacia Disease Monitoring Program

NCT04783428Tumor-induced Osteomalacia (TIO)

Ultragenyx Pharmaceutical Inc

Observational

Connecticut, Indiana, Maryland, Tennessee, Virginia

2022-01-31

Recruiting

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC

DrugsPembrolizumab KEYTRUDA·Pemetrexed·Carboplatin

Synthekine

Phase 1/2

364

Arizona, California, Connecticut, District of Columbia, Georgia, Illinois, Maryland, Massachusetts

2022-01-25

Active, closed

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT05197049Crohn Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

350

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2022-01-19

By invitation

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

NCT05127954Migraine

DrugUbrogepant

AbbVie

Phase 3

1,200

Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2022-01-14

Active, closed

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD

DrugsEylea·Aflibercept

AbbVie

Phase 3

735

Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois

2022-01-13

Active, closed

Screening for High Frequency Malignant Disease

NCT05117840Lung Cancer

Guardant Health, Inc.

Observational

12,000

Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Illinois

2022-01-13

Recruiting

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

NCT05125302Migraine

DrugUbrogepant

AbbVie

Phase 3

1,059

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2022-01-13

Active, closed

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT05067634Partial Epilepsy

SK Life Science, Inc.

Phase 3

140

Arizona, California, Connecticut, Georgia, Maryland, Minnesota, New Jersey, New York

2022-01-10

Recruiting

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

NCT05102019Refractory Angina

Shockwave Medical, Inc.

Not applicable

380

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois

2022-01-04

Active, closed

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

NCT04947319Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma

DrugTirabrutinib

Ono Pharmaceutical Co., Ltd.

Phase 2

119

Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia

2021-12-29

Active, closed

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 2

210

Arizona, Arkansas, California, Connecticut, Florida, Indiana, Massachusetts, Michigan

2021-12-28

Active, closed

INSPIRE Pipeline™ Shield Post Approval Study

NCT05071963Intracranial Aneurysm

Medtronic Neurovascular Clinical Affairs

Observational

246

Alabama, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri, New York

2021-12-20

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Arizona, California, Colorado, Connecticut, Delaware, Florida, Illinois, Indiana

2021-12-14

Recruiting

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

NCT04853251Neovascular Age-related Macular Degeneration

DrugsLucentis·Ranibizumab

Genentech, Inc.

Phase 4

188

Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa

2021-12-14

Active, closed

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281Relapsing Multiple Sclerosis

DrugsTeriflunomide·Remibrutinib

Novartis Pharmaceuticals

Phase 3

1,007

Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana, Kansas

2021-12-13

Active, closed

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

DrugsZirabev·Taxotere·Avastin·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

643

Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky

2021-12-13

Active, closed

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

NCT05079282Relapsed or Refractory T Cell Lymphoma

DrugONO-4685

Ono Pharmaceutical Co., Ltd.

Phase 1

217

Alabama, California, Connecticut, Georgia, Massachusetts, Michigan, Missouri, New Jersey

2021-12-10

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer

DrugsRLY-2608·Atirmociclib·Ribociclib·Palbociclib

Relay Therapeutics, Inc.

Phase 1

930

Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Massachusetts

2021-12-08

Recruiting

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

350

Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Hawaii, Idaho

2021-12-07

Active, closed

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

NCT05023486Advanced or Metastatic Solid Tumor Malignancies

DrugPrilukae

Novita Pharmaceuticals, Inc.

Phase 1/2

121

Arizona, Arkansas, California, Connecticut, Florida, Indiana, Kansas, Michigan

2021-12-07

Recruiting

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

NCT05164172Migraine

DrugEptinezumab

H. Lundbeck A/S

Phase 3

600

Connecticut, Florida, Kentucky, Maryland, Michigan, New York, North Carolina, Ohio

2021-12-01

Recruiting

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

NCT05125016Metastatic Castration-resistant Prostate Cancer

DrugsNezastomig·REGN4336

Regeneron Pharmaceuticals

Phase 1/2

228

California, Connecticut, Kentucky, Maryland, New Jersey, New York, North Carolina, Ohio

2021-11-30

Active, closed

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428Atherosclerotic Cardiovascular Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

17,004

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia

2021-11-23

Active, closed

A Study of NDI 1150-101 in Patients With Solid Tumors

NCT05128487Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer

DrugPembrolizumab

Nimbus Saturn, Inc.

Phase 1/2

106

Arizona, Connecticut, District of Columbia, Florida, Kentucky, Maryland, Michigan, Minnesota

2021-11-05

Recruiting

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT

NCT04862468Thrombosis, Deep Vein, Iliofemoral; Thrombosis

Mercator MedSystems, Inc.

Phase 2

Arizona, California, Connecticut, Florida, Georgia, Louisiana, Maryland, New Jersey

2021-10-29

Active, closed

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer

DrugsHerzuma·Perjeta·Herceptin·Adriamycin

AstraZeneca

Phase 3

927

Arkansas, California, Connecticut, Indiana, Kentucky, Louisiana, Minnesota, Nevada

2021-10-25

Recruiting

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223Metastatic Colorectal Cancer

DrugsDivarasib·Tiragolumab·Inavolisib·Folfiri

Hoffmann-La Roche

Phase 1

542

Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana

2021-10-22

Active, closed

Osteosarcoma Maintenance Therapy With OST31-164

NCT04974008Bone Cancer

Emerald Clinical Inc.

Phase 2

California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois, Maryland

2021-10-21

Active, closed

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

NCT05198674Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases

Medtronic Vascular

Not applicable

1,899

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2021-10-20

Active, closed

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169Multiple Myeloma

DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

587

Alabama, California, Connecticut, Georgia, Massachusetts, Michigan, Ohio, Pennsylvania

2021-10-14

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 1

520

California, Colorado, Connecticut, Illinois, Indiana, Louisiana, Michigan, New York

2021-10-13

By invitation

SPI-1005 Treatment in Moderate COVID-19 Patients

NCT04484025Covid19, Corona Virus Infection, Coronavirus, Coronavirus Infection

DrugEbselen

Sound Pharmaceuticals, Incorporated

Phase 2

Connecticut, Idaho, Kansas, Missouri, North Carolina, Texas

2021-10-12

Recruiting

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

NCT04889872Aortic Stenosis, Calcific, Aortic Valve Stenosis

Edwards Lifesciences

Not applicable

2,250

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho

2021-10-12

Active, closed

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075Conventional Chondrosarcoma

DrugINBRX-109

Inhibrx Biosciences, Inc

Phase 2

206

Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Maryland

2021-09-23

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136Primary Biliary Cholangitis, PBC

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

333

California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa, Louisiana

2021-09-22

Active, closed

Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns

NCT04090424Burns

PolyNovo Biomaterials Pty Ltd.

Not applicable

150

Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Iowa

2021-09-21

Active, closed

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

600

Arizona, California, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts

2021-09-20

Active, closed

OCS Heart Perfusion Post-Approval Registry

NCT05047068Transplant

TransMedics

Observational

350

California, Connecticut, Florida, Georgia, Illinois, Kentucky, Massachusetts, Michigan

2021-09-13

Active, closed

A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

NCT04537377Wilson's Disease

Vivet Therapeutics SAS

Phase 1/2

California, Connecticut, Florida, Michigan, North Carolina, Texas

2021-09-03

Active, closed

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

NCT05067140Prostate Cancer Metastatic

DrugsLuxdegalutamide·Abiraterone·Prednisolone·Prednisone

Novartis Pharmaceuticals

Phase 1/2

164

California, Connecticut, Florida, Maryland, Massachusetts, Michigan, New York, Pennsylvania

2021-09-02

Active, closed

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

NCT05035212Lower Respiratory Tract Illness

DrugRSVpreF

Pfizer

Phase 3

38,861

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho

2021-08-31

Active, closed

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210Arthritis, Psoriatic

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 4

411

Arizona, Arkansas, California, Connecticut, Florida, Illinois, Maryland, Michigan

2021-08-30

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

NCT04961996Early Breast Cancer

DrugGiredestrant

Hoffmann-La Roche

Phase 3

4,170

Alabama, California, Colorado, Connecticut, Florida, Illinois, Kansas, Kentucky

2021-08-27

Active, closed

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

NCT05026866Alzheimer Disease

DrugDonanemab

Eli Lilly and Company

Phase 3

2,996

Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho

2021-08-27

Active, closed

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728NASH - Nonalcoholic Steatohepatitis

Inventiva Pharma

Phase 3

1,000

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2021-08-19

Active, closed

STOP Persistent AF PAS

NCT05005949Persistent Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

400

Connecticut, Florida, Illinois, Michigan, Ohio, Texas

2021-08-19

Active, closed

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893Multiple Myeloma

DrugsCilta-cel·Bortezomib·Lenalidomide·Fludarabine

Janssen Research & Development, LLC

Phase 3

743

California, Connecticut, Florida, Iowa, Kentucky, Maryland, Massachusetts, Michigan

2021-08-19

Active, closed

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

NCT05007782Advanced Solid Tumor

DrugsDenikitug·Zimberelimab

Gilead Sciences

Phase 1

304

California, Connecticut, Massachusetts, Tennessee, Texas, Wisconsin

2021-08-18

Active, closed

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT04976634Neoplasm Malignant

DrugsBelzutifan·Lenvatinib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

730

Arizona, California, Connecticut, District of Columbia, Florida, Maryland, Michigan, New York

2021-08-18

Active, closed

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

NCT04624230Ulcerative Colitis

DrugTofacitinib

Pfizer

Phase 3

118

California, Connecticut, Florida, Georgia, Massachusetts, New York, Ohio, Pennsylvania

2021-08-12

Active, closed

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

NCT05704361Multiple Sclerosis

Hoffmann-La Roche

Phase 1

119

California, Connecticut

2021-08-11

Recruiting

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

NCT04787042Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma

DrugsObinutuzumab·Keytruda·Pembrolizumab

Simcha IL-18, Inc.

Phase 1/2

316

Arizona, Colorado, Connecticut, Florida, Massachusetts, New York

2021-08-06

Active, closed

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709Muscle Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

712

California, Connecticut, District of Columbia, Florida, Idaho, Illinois, Indiana, Iowa

2021-08-05

Active, closed

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms

DrugsOlomorasib·Erbitux·Cetuximab·Pemetrexed

Eli Lilly and Company

Phase 1/2

540

Alabama, California, Connecticut, Florida, Indiana, Louisiana, Massachusetts, New Hampshire

2021-07-19

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

NCT04951622Myasthenia Gravis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

199

Arizona, California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts

2021-07-15

Active, closed

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

NCT04857034Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 2

Arizona, California, Connecticut, Florida, Michigan, Missouri, New York, North Carolina

2021-07-12

Recruiting

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

NCT04965675Chronic Migraine in Children

DrugEptinezumab

H. Lundbeck A/S

Phase 3

285

Connecticut, District of Columbia, Florida, Georgia, Kentucky, Maryland, Michigan, New York

2021-06-30

Active, closed

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

NCT04925752Pre-Exposure Prophylaxis of HIV Infection

DrugsF/TAF·Descovy·F/TDF·Lenacapavir

Gilead Sciences

Phase 3

3,292

Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois

2021-06-28

Active, closed

Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

NCT04806451Congenital Adrenal Hyperplasia

DrugCrinecerfont

Neurocrine Biosciences

Phase 3

103

Alabama, California, Colorado, Connecticut, District of Columbia, Georgia, Indiana, Massachusetts

2021-06-25

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfiri

Mirati Therapeutics Inc.

Phase 3

461

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia

2021-06-24

By invitation

Distal Evaluation of Functional Performance with Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

NCT04451044Coronary Artery Disease, Ischemic Heart Disease

Philips Clinical & Medical Affairs Global

Not applicable

3,212

Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida

2021-06-17

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/connecticut?page=2

Query this register directly

GET /api/trials?country=usa&status=recruiting&format=json Try it now →

Clinical Trials in Connecticut, 2026

Trials with a site in Connecticut

About this register

How many clinical trials are recruiting in Connecticut?